Sunday, 15 November 2026European Markets

SCOR SE And TREASURE Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Loading stream...

(vianews) - scor se (scr.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
scor se (scr.pa) €32.07 9.76% 2.91%
treasure (tre.ol) kr25.70 2.88% 13.4%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. scor se (scr.pa)

9.76% forward dividend yield and 2.91% return on equity

scor se, together with its subsidiaries, provides life and non-life reinsurance products in europe, the middle east, africa, the americas, latin america, and asia pacific. it operates in two segments, scor p&c and scor l&h. the scor p&c segment offers reinsurance products in the areas of property, motors, casualty treaties, credit and surety, decennial insurance, aviation, marine and energy, engineering, agricultural risks, and property catastrophes; specialties insurance products, including business solutions, political and credit risks, cyber, and environmental liability; and business ventures and partnerships. the scor l&h segment provides life reinsurance products, such as protection for mortality, morbidity, behavioral risks, disability, long-term care, critical illness, medical, and personal accident. this segment also provides financial solutions that combine traditional life reinsurance with financial components and provide liquidity, balance sheet, solvency, and income improvements to clients; longevity solutions that include products covering the risk of negative deviation from expected results due to the insured or annuitant living longer than assumed in the pricing of insurance covers provided by insurers or pension funds; and distribution solutions. in addition, it is involved in the asset management business. scor se was founded in 1970 and is headquartered in paris, france.

earnings per share

as for profitability, scor se has a trailing twelve months eps of €4.45.

pe ratio

scor se has a trailing twelve months price to earnings ratio of 7.21. meaning, the purchaser of the share is investing €7.21 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.91%.

volatility

scor se's last week, last month's, and last quarter's current intraday variation average was a negative 0.72%, a positive 0.43%, and a positive 2.08%.

scor se's highest amplitude of average volatility was 1.04% (last week), 1.09% (last month), and 2.08% (last quarter).

more news about scor se.

2. treasure (tre.ol)

2.88% forward dividend yield and 13.4% return on equity

treasure asa, through its 11% interest in hyundai glovis co. ltd., provides transportation and logistics services in south korea. the company was incorporated in 2016 and is based in lysaker, norway. treasure asa is a subsidiary of wilh. wilhelmsen holding asa.

earnings per share

as for profitability, treasure has a trailing twelve months eps of kr4.56.

pe ratio

treasure has a trailing twelve months price to earnings ratio of 5.64. meaning, the purchaser of the share is investing kr5.64 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.4%.

more news about treasure.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com